Genotyping, local prevalence and international dissemination of β‐lactamase‐producing Kingella kingae strains. (14th June 2014)

• Record Type: Journal Article
• Authors: Basmaci, R.; Bonacorsi, S.; Bidet, P.; Balashova, N. V.; Lau, J.; Muñoz‐Almagro, C.; Gene, A.; Yagupsky, P.; Tassios, P.
• Is Part Of: Clinical microbiology and infection. Volume 20:Number 11(2014:Nov.)
• Page Start: O811
• Page End: O817
• Publication Date: 2014-06-14
• Subjects: Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1111/1469-0691.12648
• Languages: English
• ISSNs: 1198-743X

Abstract

<abstract abstract-type="main" id="clm12648-abs-0001"> <title>Abstract</title> <p> <italic>β</italic>‐lactamase production has been sporadically reported in the emerging <italic>Kingella kingae</italic> pathogen but the phenomenon has not been studied in‐depth. We investigated the prevalence of <italic>β</italic>‐lactamase production among <italic>K. kingae</italic> isolates from different geographical origins and genetically characterized <italic>β</italic>‐lactamase‐producing strains. Seven hundred and seventy‐eight isolates from Iceland, the USA, France, Israel, Spain and Canada were screened for <italic>β</italic>‐lactamase production and, if positive, were characterized by PFGE and MLST genotyping, as well as <italic>rtx</italic>A, <italic>por</italic>, <italic> bla</italic><sub><italic>TEM</italic></sub> and 16S rRNA sequencing. <italic>β</italic>‐lactamase was identified in invasive strains from Iceland (<italic>n</italic> = 4/14, 28.6%), the USA (<italic>n</italic> = 3/15, 20.0%) and Israel (<italic>n</italic> = 2/190, 1.1%) and in carriage strains in the USA (<italic>n</italic> = 5/17, 29.4%) and Israel (<italic>n</italic> = 66/429, 15.4%). No French, Spanish or Canadian isolates were <italic>β</italic>‐lactamase producers. Among <italic>β</italic>‐lactamase producers, a perfect congruency between the different typing methods was observed. Surprisingly, all US and Icelandic <italic>β</italic>‐lactamase‐producing isolates were almost indistinguishable, belonged to the major international invasive PFGE clone K/MLST ST‐6, but differed from the four genetically unrelated Israeli <italic>β</italic>‐lactamase‐producing clones. Representative strains of different genotypes produced the TEM‐1 enzyme. <italic>K. kingae β</italic>‐lactamase producers exhibit a clear clonal distribution and have dissimilar invasive potential. The presence of the enzyme in isolates belonging to the major worldwide invasive clone K/ST‐6 highlights the possible spread of <italic>β</italic>‐lactam resistance, and emphasizes the importance of routine testing of all <italic>K. kingae</italic> clinical isolates for <italic>β</italic>‐lactamase production.</p> </abstract>